Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 4:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 43 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vitrectomy surgery Clear all
Not yet recruiting Phase 4 Interventional

Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.

NCT07864480
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy, Diabetic Retinopathy, Diabetes
Interventions
PDS Implant filled with 100 mg/mL Ranibizumab, Ranibizumab
Device · Drug
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 4:27 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Anti-VEGF vs. Prompt Vitrectomy for VH From PDR

NCT02858076
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy, Vitreous Hemorrhage
Interventions
2-mg Intravitreous Aflibercept Injection, Prompt Vitrectomy Plus Panretinal Photocoagulation
Drug · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
60
States / cities
Campbell, California • Glendale, California • Huntington Beach, California + 50 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 31, 2026, 4:27 PM EDT
Completed Not applicable Interventional

The Effects of a Music Therapist Designed Listening Program on Intraoperative Vitrectomy

NCT03147235
View directory record Official record
Conditions
Pain, Postoperative, Music Therapy
Interventions
vitrectomy with music listening
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 31, 2026, 4:27 PM EDT
Completed No phase listed Observational

A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events

NCT03479736
View directory record Official record
Conditions
Retinal Detachment, Achilles Tendon, Aneurysm, Dissecting
Interventions
Oral Fluoroquinolones (FQ), Other Antibiotics, Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
117,911 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 31, 2026, 4:27 PM EDT
Not listed Not applicable Interventional

Stem Cell Ophthalmology Treatment Study

NCT01920867
View directory record Official record
Conditions
Retinal Disease, Macular Degeneration, Hereditary Retinal Dystrophy, Optic Nerve Disease, Glaucoma
Interventions
RB (Retrobulbar), ST (Subtenon), IV (Intravenous), IVIT (Intravitreal), IO (Intraocular)
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Westport, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 31, 2026, 4:27 PM EDT
Completed Not applicable Interventional

EFFECTIVENESS AND SAFETY ASSESSMENT OF THE VISTA VITRECTOMY PROBE

NCT07140692
View directory record Official record
Conditions
Vitreous Floaters, Vitreous Opacities
Interventions
Vitrectomy
Device
Lead sponsor
The Eye Centers of Racine and Kenosha
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Kenosha, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Oct 31, 2026, 4:27 PM EDT
Completed Phase 2 Interventional Results available

Aflibercept Injection for Proliferative Diabetic Retinopathy

NCT01805297
View directory record Official record
Conditions
Vitreous Hemorrhage
Interventions
Intravitreal Aflibercept Injection, Standard Vitrectomy
Drug · Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 31, 2026, 4:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Beveled-Tip Versus(vs) Standard-Tip Vitrectomy Probe

NCT04076072
View directory record Official record
Conditions
Vitrectomy
Interventions
Utravit High-Speed 10000 cpm Beveled Probe, standard vitrector probe- Alcon (non-beveled) Ultravit 7500 cpm
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 31, 2026, 4:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Dropless Pars Plana Vitrectomy Study

NCT05331664
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment
Interventions
Pars plana vitrectomy, Triamcinolone Acetonide 40mg/mL, Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin, Prednisolone 1%, Atropine 1%
Procedure · Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years and older
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 31, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy

NCT04136366
View directory record Official record
Conditions
Proliferative Vitreoretinopathy
Interventions
ADX-2191 (intravitreal methotrexate 0.8%), Standard surgical care procedure
Drug · Other
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 31, 2026, 4:27 PM EDT
Terminated No phase listed Observational

Necessity of Post-operative Eye Drops

NCT07396831
View directory record Official record
Conditions
Pars Plana Vitrectomy, Scleral Buckling, Surgical Outcomes, Infection Prophylaxis
Interventions
Not listed
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 31, 2026, 4:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Scheimpflug Photos of the Crystalline Lens in Patients Who Have Undergone Vitrectomy Surgery and Controls

NCT00406263
View directory record Official record
Conditions
Nuclear Sclerotic Cataract
Interventions
Scheimpflug crystalline lens photographs
Procedure
Lead sponsor
Barnes Retina Institute
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Oct 31, 2026, 4:27 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Use of Preoperative Gas in Eyes With Macula-off Rhegmatogenous Retinal Detachment (RRD)

NCT07855770
View directory record Official record
Conditions
Retinal Detachment Rhegmatogenous
Interventions
Intravitreal 100% C3F8 Injection, Pars plana vitrectomy or pars plana vitrectomy with scleral buckle
Procedure
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 31, 2026, 4:27 PM EDT
Completed Not applicable Interventional

A Study to Evaluate the Safety and Performance of the Vista Probe for Vitrectomy Surgery

NCT05689333
View directory record Official record
Conditions
Vitrectomy
Interventions
Vista Vitrectomy Probe
Device
Lead sponsor
VISTA Ophthalmics
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Bradenton, Florida • Bala-Cynwyd, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 31, 2026, 4:27 PM EDT
Completed Not applicable Interventional

Safety and Efficacy of Silicone Oil Tamponade for Surgical Attenuation of Radiation Damage in Choroidal Melanoma

NCT01460810
View directory record Official record
Conditions
Choroidal Melanoma
Interventions
1000CsK Silicon Oil Tamponade
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 31, 2026, 4:27 PM EDT
Recruiting Not applicable Interventional

Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM

NCT05145491
View directory record Official record
Conditions
Epiretinal Membrane
Interventions
Immediate Vitrectomy, Deferred Vitrectomy
Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
47
States / cities
Scottsdale, Arizona • Glendale, California • Huntington Beach, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 31, 2026, 4:27 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa

NCT07174726
View directory record Official record
Conditions
X-Linked Retinitis Pigmentosa (XLRP)
Interventions
Adeno-associated virus vector expressing a human RPGR gene
Biological
Lead sponsor
Beacon Therapeutics
Industry
Eligibility
12 Years to 50 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
6
States / cities
Jacksonville, Florida • Miami, Florida • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 31, 2026, 4:27 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)

NCT00412958
View directory record Official record
Conditions
Vitrectomy
Interventions
Ocriplasmin 25µg, Ocriplasmin 75µg, Ocriplasmin 125µg, Placebo
Drug
Lead sponsor
ThromboGenics
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
20
States / cities
Tucson, Arizona • Huntington Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Oct 31, 2026, 4:27 PM EDT
Completed Phase 4 Interventional Results available

Oral Versus Intravenous Sedation for Ocular Procedures

NCT03246724
View directory record Official record
Conditions
Surgery, Sedation
Interventions
Triazolam, Midazolam, Microcrystalline Cellulose, Sodium chloride 0.9%
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Oct 31, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of BIIB111 for the Treatment of Choroideremia

NCT03496012
View directory record Official record
Conditions
Choroideremia
Interventions
BIIB111
Genetic
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older · Male only
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 31, 2026, 4:27 PM EDT
Terminated Not applicable Interventional Results available

Safety and Effectiveness of Ozurdex Steroid Implants for DME After Vitrectomy Surgery

NCT01788475
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone
Drug
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Peabody, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 31, 2026, 4:27 PM EDT
Not listed Phase 4 Interventional

Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.

NCT04501367
View directory record Official record
Conditions
Vitrectomy, Macular Pucker, Retinal Edema
Interventions
Dexamethasone Intracanalicular Insert, 0.4 mg, Prednisone acetate 1%
Drug
Lead sponsor
Kovach Eye Institute
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Elmhurst, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 31, 2026, 4:27 PM EDT
Completed Phase 1 Interventional

INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study

NCT04505566
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Ketorolac 0.45% ophthalmic solution, Placebo - Preservative-free artificial tears, Aqueous PGE2 and inflammatory cytokines measurements
Drug · Other
Lead sponsor
Stephen J. Kim, MD
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 31, 2026, 4:27 PM EDT
Completed Not applicable Interventional Results available

Clinical Comparison of 27+® and 23-gauge ULTRAVIT® 7500 Cpm Vitrectomy Outcomes

NCT02477605
View directory record Official record
Conditions
Vitreoretinal Disease
Interventions
CONSTELLATION® 27-gauge Combined Surgical Pak, CONSTELLATION® 23-gauge Combined Surgical Pak, Vitrectomy surgery
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
22 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 31, 2026, 4:27 PM EDT